Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ
Closed
Oct 7, 2026
Day's Range
222.9652 wk Range
197.81Overview - ALNY - Alnylam Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
29.07B
P/E (Trailing)
‪38.34‬
P/E (Forward)
‪17.61‬
PEG Ratio
‪-0.11‬
Price / Sales (TTM)
‪6.11‬
Price / Book
‪21.70‬
EV / EBITDA
‪27.57‬
Profitability
Gross Margin
‪76.88%‬
Profit Margin
‪16.12%‬
Operating Margin
‪17.92%‬
Return on Assets
‪12.34%‬
Return on Equity
‪96.55%‬
Ownership
Shares Outstanding
133.73M
Float
133.23M
Short % of Shares Outstanding
‪7.16%‬
Held by Insiders
‪0.18%‬
Held by Institutions
‪101.81%‬
Price stats
Beta
‪0.30‬
50-Day Avg
‪241.49‬
200-Day Avg
‪302.88‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
29 analysts
Average price target
‪$ 370.20‬Shariah Compliance
Report Date: Feb 15, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ALNY - Alnylam Pharmaceuticals, Inc.
Peers - ALNY - Alnylam Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
- AXSMNASDAQAxsome Therapeutics Inc.9.37BMarket Cap+33.09%52-week change-48.69P/E (Trailing)‪-24.67%‬Profit Margin
Profile Summary - ALNY - Alnylam Pharmaceuticals, Inc.
About
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on rare genetic and cardiometabolic conditions. Its current portfolio…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
